Literature DB >> 19565559

Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial.

A E van der Bijl1, Y K O Teng, M van Oosterhout, F C Breedveld, C F Allaart, T W J Huizinga.   

Abstract

OBJECTIVE: To evaluate the efficacy and safety of intraarticular infliximab compared with intraarticular methylprednisolone in patients with gonarthritis.
METHODS: In 23 patients with recurrent gonarthritis despite previous intraarticular corticosteroid therapy, a total of 41 intraarticular injections (20 infliximab and 21 methylprednisolone) were performed in 28 knees. Initial therapy was randomly assigned, and crossover therapy was eligible within 3 months. The clinical effect was assessed during 6 months of followup. The primary outcome was event-free survival, defined as the time after treatment until local retreatment was performed and/or nonimprovement of the knee joint score. Adverse effects were recorded during followup.
RESULTS: All patients treated with intraarticular infliximab had an insufficient response. In contrast, 8 of the 21 intraarticular methylprednisolone injections were effective (P = 0.004). Between groups, no differences in the patients' age, disease duration, number of disease-modifying antirheumatic drugs, or previous intraarticular methylprednisolone were observed. Reported adverse effects were not related to therapy.
CONCLUSION: Treatment with intraarticular infliximab injection was not effective in patients with a chronically inflamed knee joint. Intraarticular injection with methylprednisolone was superior despite previous intraarticular corticosteroid therapy. Further investigation is needed to provide these patients with a better alternative.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19565559     DOI: 10.1002/art.24513

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  6 in total

1.  Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare.

Authors:  Francesco Carubbi; Luigi Zugaro; Paola Cipriani; Armando Conchiglia; Lorenzo Gregori; Cristino Danniballe; Maria Letizia Pistoia; Vasiliki Liakouli; Piero Ruscitti; Francesco Ciccia; Giovanni Triolo; Carlo Masciocchi; Roberto Giacomelli
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-18       Impact factor: 3.219

2.  Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug.

Authors:  David Stepensky
Journal:  Clin Pharmacokinet       Date:  2012-07-01       Impact factor: 6.447

Review 3.  Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Authors:  Jasvinder A Singh; George A Wells; Robin Christensen; Elizabeth Tanjong Ghogomu; Lara Maxwell; John K Macdonald; Graziella Filippini; Nicole Skoetz; Damian Francis; Luciane C Lopes; Gordon H Guyatt; Jochen Schmitt; Loredana La Mantia; Tobias Weberschock; Juliana F Roos; Hendrik Siebert; Sarah Hershan; Michael Pt Lunn; Peter Tugwell; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

4.  Anticytokine therapy for osteoarthritis: evidence to date.

Authors:  Charles J Malemud
Journal:  Drugs Aging       Date:  2010-02-01       Impact factor: 3.923

5.  Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint.

Authors:  Ugo Fiocco; Paolo Sfriso; Francesca Oliviero; Pascale Roux-Lombard; Elena Scagliori; Luisella Cozzi; Francesca Lunardi; Fiorella Calabrese; Maristella Vezzù; Serena Dainese; Beatrice Molena; Anna Scanu; Roberto Nardacchione; Leopoldo Rubaltelli; Jean Michel Dayer; Leonardo Punzi
Journal:  Arthritis Res Ther       Date:  2010-07-19       Impact factor: 5.156

Review 6.  Optimal dose of etanercept in the treatment of rheumatoid arthritis.

Authors:  Elizabeth Mary Curtis; Jonathan Lewis Marks
Journal:  Open Access Rheumatol       Date:  2014-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.